NO308250B1 - 6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse - Google Patents

6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse

Info

Publication number
NO308250B1
NO308250B1 NO972198A NO972198A NO308250B1 NO 308250 B1 NO308250 B1 NO 308250B1 NO 972198 A NO972198 A NO 972198A NO 972198 A NO972198 A NO 972198A NO 308250 B1 NO308250 B1 NO 308250B1
Authority
NO
Norway
Prior art keywords
naphthyridines
arylpyrido
pyrimidines
pharmaceutical compositions
useful
Prior art date
Application number
NO972198A
Other languages
English (en)
Norwegian (no)
Other versions
NO972198L (no
NO972198D0 (no
Inventor
Clifton John Blankley
Annette Marian Doherty
James Marino Hamby
Robert Lee Panek
Mel Conrad Schroeder
Howard Daniel Hollis Showalter
Cleo Connolly
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/539,410 external-priority patent/US5733913A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO972198L publication Critical patent/NO972198L/no
Publication of NO972198D0 publication Critical patent/NO972198D0/no
Publication of NO308250B1 publication Critical patent/NO308250B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
NO972198A 1994-11-14 1997-05-13 6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse NO308250B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33905194A 1994-11-14 1994-11-14
US08/539,410 US5733913A (en) 1994-11-14 1995-11-06 6-Aryl pyrido 2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
PCT/US1995/014700 WO1996015128A2 (en) 1994-11-14 1995-11-13 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION

Publications (3)

Publication Number Publication Date
NO972198L NO972198L (no) 1997-05-13
NO972198D0 NO972198D0 (no) 1997-05-13
NO308250B1 true NO308250B1 (no) 2000-08-21

Family

ID=26991470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972198A NO308250B1 (no) 1994-11-14 1997-05-13 6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse

Country Status (25)

Country Link
US (1) US5952342A (zh)
EP (1) EP0790997B1 (zh)
CN (1) CN1085666C (zh)
AT (1) ATE190978T1 (zh)
AU (1) AU711426B2 (zh)
BG (1) BG63162B1 (zh)
CZ (1) CZ286160B6 (zh)
DE (1) DE69515898T2 (zh)
DK (1) DK0790997T3 (zh)
ES (1) ES2146782T3 (zh)
FI (1) FI971953A (zh)
GE (1) GEP20012444B (zh)
GR (1) GR3033439T3 (zh)
HU (1) HUT76853A (zh)
IL (1) IL115970A (zh)
MD (1) MD1861G2 (zh)
MX (1) MX9702245A (zh)
NO (1) NO308250B1 (zh)
NZ (1) NZ296456A (zh)
PL (1) PL181893B1 (zh)
PT (1) PT790997E (zh)
RU (1) RU2191188C2 (zh)
SK (1) SK281724B6 (zh)
TJ (1) TJ342B (zh)
WO (1) WO1996015128A2 (zh)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP1806348A3 (en) * 1997-02-05 2008-01-02 Warner-Lambert Company LLC Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
ES2301194T3 (es) * 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
EP1003745B1 (en) * 1997-08-20 2004-12-29 Warner-Lambert Company Llc Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
CN1138778C (zh) * 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
EE200200405A (et) * 2000-01-25 2003-12-15 Warner-Lambert Company Pürido[2,3-d]pürimidiin-2,7-diamiinid kui kinaasiinhibiitorid
WO2002008224A1 (en) 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
AU9378401A (en) * 2000-08-31 2002-03-13 Hoffmann La Roche 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
ATE320255T1 (de) * 2001-01-19 2006-04-15 Smithkline Beecham Corp Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
ATE305303T1 (de) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2003064421A1 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine derivatives
AU2003211594A1 (en) * 2002-03-05 2003-09-16 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
ATE374201T1 (de) 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
AU2004289428B2 (en) 2003-11-13 2010-06-03 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP2260849A1 (en) 2004-01-21 2010-12-15 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
KR100881050B1 (ko) * 2004-03-15 2009-01-30 에프. 호프만-라 로슈 아게 신규 디클로로―페닐―피리도 [2,3-ｄ] 피리미딘 유도체, 그들의 제조 및 약제로서의 용도
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) * 2004-09-21 2007-08-08 霍夫曼-拉罗奇有限公司 用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006045096A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2007060028A1 (en) * 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
JP2009504665A (ja) * 2005-08-09 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US20070082920A1 (en) * 2005-10-06 2007-04-12 Yongsheng Song NAD+-dependent DNA ligase inhibitors
RU2445315C2 (ru) * 2005-11-22 2012-03-20 Кудос Фармасьютиклз Лимитед ПРОИЗВОДНЫЕ ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
ATE439361T1 (de) 2006-01-31 2009-08-15 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
SI2074122T1 (sl) 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
JP5813626B2 (ja) 2009-04-22 2015-11-17 レスバーロジックス コーポレイション 新規抗炎症剤
ES2347630B1 (es) * 2009-04-29 2011-09-08 Universitat Ramon Llull Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
EP2332939A1 (en) * 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
KR102011641B1 (ko) 2011-11-01 2019-08-19 리스버로직스 코퍼레이션 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
ES2916220T3 (es) * 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
MX2015011514A (es) 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos.
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
MX2017013248A (es) * 2015-04-14 2018-07-06 Eisai R&D Man Co Ltd Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
CN104774183B (zh) * 2015-04-24 2017-10-13 合肥新诺华生物科技有限公司 一种甲酰基瑞舒伐汀钙中间体的制备方法
WO2018023081A1 (en) * 2016-07-29 2018-02-01 Achaogen, Inc. 6-phenylpyrido[2,3-d]pyrimidine compounds as antibacterial agents
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
CN112313327B (zh) 2018-04-23 2024-04-19 千纸鹤治疗公司 增殖抑制剂
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220099958A (ko) * 2019-10-01 2022-07-14 골드핀치 바이오 인코포레이티드 Cdk5의 치환된 1,6-나프티리딘 억제제
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
DE4131029A1 (de) * 1991-09-18 1993-07-29 Basf Ag Substituierte pyrido (2,3-d) pyrimidine als antidots

Also Published As

Publication number Publication date
SK60997A3 (en) 1998-05-06
GR3033439T3 (en) 2000-09-29
AU711426B2 (en) 1999-10-14
IL115970A0 (en) 1996-01-31
BG101326A (en) 1998-04-30
GEP20012444B (en) 2001-05-25
AU4107896A (en) 1996-06-06
ES2146782T3 (es) 2000-08-16
NO972198L (no) 1997-05-13
HUT76853A (en) 1997-12-29
US5952342A (en) 1999-09-14
SK281724B6 (sk) 2001-07-10
PL181893B1 (pl) 2001-10-31
RU2191188C2 (ru) 2002-10-20
CN1169726A (zh) 1998-01-07
MD1861F2 (en) 2002-02-28
MD1861G2 (ro) 2002-09-30
PL320169A1 (en) 1997-09-15
IL115970A (en) 1999-06-20
MD970187A (en) 1999-02-28
WO1996015128A3 (en) 1996-07-11
EP0790997B1 (en) 2000-03-22
CN1085666C (zh) 2002-05-29
NO972198D0 (no) 1997-05-13
DE69515898D1 (de) 2000-04-27
DE69515898T2 (de) 2000-08-17
FI971953A (fi) 1997-05-12
NZ296456A (en) 1999-09-29
CZ139097A3 (cs) 1998-02-18
MX9702245A (es) 1997-06-28
DK0790997T3 (da) 2000-08-21
CZ286160B6 (cs) 2000-01-12
EP0790997A2 (en) 1997-08-27
FI971953A0 (fi) 1997-05-07
PT790997E (pt) 2000-06-30
ATE190978T1 (de) 2000-04-15
TJ342B (en) 2002-10-06
WO1996015128A2 (en) 1996-05-23
BG63162B1 (bg) 2001-05-31

Similar Documents

Publication Publication Date Title
NO308250B1 (no) 6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse
IL117923A0 (en) Pyrido [2,3-d] pyrimidine derivatives and pharmaceutical compositions containing them
CA2291222A1 (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CY1109484T1 (el) Παραγωγα πυριμιδιν-5-ονης ως αναστολεις της ldl-pla2
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
NO20005928D0 (no) Bicykliske pyrimidiner og bicykliske 3,4-dihydropyrimidiner som inhibitorer av cellulær proliferasjon
BR9706973A (pt) Novos compostos de imidazol substituídos
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
ATE294802T1 (de) 3-alkylimidazopyridine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees